MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

22.69 -0.57 (-2.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery ↗
 
Via Benzinga
News headline image
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug ↗
 
Via Benzinga
News headline image
Pacira BioSciences' Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
Pacira BioSciences: Q2 Earnings Insights ↗
  Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
From Pacira BioSciences
Via GlobeNewswire
News headline image
Expert Ratings For Pacira BioSciences ↗
Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the... 
Via Benzinga
News headline image
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know ↗
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday. 
Via Benzinga
News headline image
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark ↗
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82 ↗
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Receives Composite Rating Upgrade ↗
The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals. 
Via Investor's Business Daily
News headline image
Pacira BioSciences's Return on Invested Capital Overview ↗
Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. 
Via Benzinga
News headline image
Gilead Stock Earns Rating Upgrade After Quick Turnaround ↗
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
Pacira BioSciences: Q1 Earnings Insights ↗
Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
News headline image
28 Biggest Movers From Yesterday ↗
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
Via Benzinga
News headline image
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
News headline image
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
Via Investor's Business Daily
News headline image
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
News headline image
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating ↗
Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript ↗
PCRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story